YARD-FORCE-UK
19.1.2023 06:23:36 CET | Business Wire | Press release
David Domoney highlights the ever-growing garden trend of manicuring. Keeping a neat and tidy garden is important, especially with the rise in popularity of outdoor entertaining. From trimming hedges and edges of lawns to cleaning your patio for a pristine garden, choosing the right tool for the job is crucial. With so much choice in the market, selecting powered garden tools to make the job of garden manicuring both easy, professional and all importantly, fun is a hot topic. In partnering with Yard Force®, David Domoney hopes to encourage people into their gardens and highlight the right time to do specific green preening tasks in the year. Utilising the tools at the right time of the year ensures you get the most out of them as well as making sure your garden is in the best shape.
David said, “By selecting the right tool for the job, it enables you to get the task at hand done most effectively and efficiently, so you have more time to spend enjoying a beautiful garden. In learning when is best to trim hedges, mow the lawn and general garden maintenance, we make time in the garden so much more enjoyable whilst protecting garden wildlife. It opens doors to learning new gardening techniques that will become part of regular gardening routines for a well-cared-for garden.”
Yard Force® is an internationally recognised brand with years of industry experience and knowledge.
David continues, “Giving people access to a better gardening experience is always a good thing; with practical advice on making the most of their garden and the tools necessary to give great results with little effort. The more we can do using professional electric-powered equipment at the right time of year, leaves us more time to enjoy the garden.
I want to make the tasks in the garden both rewarding and fun and using practical power tools that take the hard work out of garden maintenance. The range of cordless products and battery-share technology makes the range hassle-free, convenient, and a more sustainable option for beginners and keen gardeners alike. Within Yard Force’s 40V range, there is the Cordless Lawnmower, Hedge Trimmer, Grass Trimmer which are really innovative products that showcase game-changing technology.”
The partnership between David Domoney and Yard Force continues to encourage budding gardeners and virtuosos to get outside and give their gardens the best care. Through instructive videos, demos, gardening tips and fantastic giveaways, the knowledge and expertise will promote the range and how to get the most from the tools.
Notes to Editors:
David Domoney:
David Domoney is a seasoned gardening television broadcaster and currently presents on ITV’s ‘Love Your Garden’, ‘Love Your Weekend’ and is also the gardening presenter for ITV’s ‘This Morning’. He is a winner of 30 RHS Medals with two Best in Show category trophies and the Prince Edward Award for Horticulture Excellence. David is also known for pioneering campaigns Cultivation Street as well as Illumination Street, brightening up Britain’s streets at Christmas. David also writes a gardening column for Grow Your Own magazine.
Yard Force UK:
Yard Force are excited and proud to announce that we have partnered with seasoned gardening television presenter David Domoney to endorse our range of innovative, durable and high-performance garden power tools.
David is best known for presenting ITV’s most popular Gardening Show ‘Love your Garden’ and is also the resident gardening presenter for ITV’s flagship daytime show ‘This Morning’.
David's 40 years’ of experience in horticulture and dynamic enthusiastic character made him the perfect choice to collaborate with to help endorse our innovative and quality lead products.
Introducing a household name to represent our brand instils the confidence we have in our products and their performance. David says:
‘Like anything in the garden, once you know how, it becomes so easy. In learning how to look after our gardens properly, using power tools where needed, we make time in the garden so much more enjoyable and open doors to learning new gardening techniques and having access to a healthy and well-cared-for garden.”
We will be working closely with David throughout the year to produce top gardening tips for you to use around the garden, create some instructive videos designed to encourage you and your family to get back outside and exciting GIVEAWAYS featuring chosen products. To be in with the chance of winning and accessing these great promotions we have created a dedicated promotional code which will enable you to receive discounts and added extras all year round! All you need to do is:
SIGN UP TO RECEIVE THE PROMOTIONAL CODE below:
www.yardforce.eu/david
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005607/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom